Thymosin alpha 1 hepatitis B trials gave mixed answers. A Taiwan study found a delayed improvement in blood markers. A U.S. study using an inactive comparison treatment did not confirm a clear benefit. These findings do not establish thymosin alpha-1 as a replacement for standard hepatitis B treatment.
The distinction matters because a better blood test and lasting protection from liver damage are different outcomes. This research mostly measured blood markers.
What did the thymosin alpha 1 hepatitis B trial ask?
Could thymosin alpha-1 help people with chronic hepatitis B, a lasting viral liver infection, lose blood markers of active infection?
Thymosin alpha-1 is a peptide, a short chain of protein building blocks. Thymalfasin is its medicine name; Zadaxin is a brand sold abroad. The discovery story follows how it reached human testing.
Chien and colleagues' 1998 Hepatology trial randomly assigned 98 patients in Taiwan, whose chronic hepatitis B had been confirmed by clinical and biopsy findings, to 26 weeks of thymalfasin (32 people), 52 weeks (34) or no specific treatment (32). All had HBeAg in their blood, according to FDA's later summary. Follow-up continued to 18 months after entry. Random assignment means chance determined the group.
What counted as a response?
The main reported result required two blood markers to fall below the study's detection limits together:
- HBV DNA: the virus's genetic material, measured in blood.
- HBeAg: hepatitis B e antigen, a viral protein used to help assess infection activity.
The researchers called this a complete virological response. That name describes their test result, rather than proving the infection had been removed from the body.
The headline result appeared after treatment ended
About four in ten patients in the shorter-treatment group met that definition, compared with about one in ten untreated patients.
| Group | Response at 18 months after entry |
|---|---|
| Thymalfasin for 26 weeks | 40.6% |
| Thymalfasin for 52 weeks | 26.5% |
| No specific treatment | 9.4% |
Only the shorter-course comparison reached statistical significance: P=0.004, versus P=0.068 for the longer course. Statistically significant means a gap that large would be unlikely if the treatment made no difference.
Response rates were similar when treatment first ended. More responses accumulated afterward. None of the responders lost HBsAg, the virus's surface protein. A pathologist who did not know the group assignments also scored liver biopsies from the 55 patients who agreed to them, and the report described significant improvement in liver inflammation in treated patients. The delayed pattern was interesting, but the longer course did not establish a clearer advantage.
What did the safety reporting show?
Chien's report described no significant side effects. That is a limited observation, not a measured zero risk for every reaction.
| Safety question | Reported finding |
|---|---|
| Overall tolerability in the 1998 trial | No significant side effects observed |
| Most common reactions across studies in the U.S. drug regulator's later review | Local irritation, redness or discomfort where injected |
| Liver-enzyme flares in a separate hepatitis B study, from the same review | 22 of 316 people had a temporary jump in a liver enzyme called ALT; treatment was interrupted in 16, and all recovered |
FDA, the U.S. Food and Drug Administration, describes those local reactions in its November 15, 2024 evaluation. They are not percentages from Chien's trial. The same review concluded that compounding with thymosin alpha-1 “may raise safety concerns,” including possible immune reactions to impurities or clumped peptide. Brief or small studies can miss uncommon problems, and tolerability findings cannot establish long-term safety for a different preparation.
The U.S. phase 3 study did not confirm the finding
The U.S. study was phase 3, a later-stage test of treatment benefit. Mutchnick and colleagues' 1999 Journal of Viral Hepatitis study enrolled 97 patients: 49 received thymalfasin and 48 received placebo, a comparison preparation without the active drug. Double-blind means patients and researchers did not know the assignments.
Participants had both HBV DNA and HBeAg in their blood. Treatment lasted six months, followed by six months of observation. Complete response required sustained loss of detectable viral DNA plus negative DNA and HBeAg tests at month 12.
Seven treated patients, 14%, responded, compared with two placebo patients, 4%. The difference did not reach statistical significance, P=0.084. The authors concluded that their findings did not confirm earlier reports.
Delayed responses also occurred in both groups: 10% with thymalfasin and 8% with placebo. An improvement after treatment therefore cannot, by timing alone, establish that treatment caused it.
What later reviewers questioned
FDA's 2024 reviewers flagged the Taiwan study's small size and lack of blinding outside the liver-tissue assessment. They also questioned its older blood test, which could miss virus levels that modern tests detect. A negative result on that older test is not interchangeable with today's result.
As of October 29, 2026, the day this article was written, a September 9 Cochrane review adds a broader assessment. It included 10 trials involving 1,349 adults; each pooled result drew on one to five of them. Most findings remained very uncertain; evidence about serious medical events was rated low certainty. Study weaknesses and imprecise estimates limited confidence.
So the question is still open, and the Taiwan trial's 40.6% is not a result a patient can count on. The broader benefits guide covers the separate research in other illnesses.
Where hepatitis B care stands today
As of October 29, 2026, the day this article was written, U.S. liver and infectious-disease specialists' guidance recommends established antiviral medicines. These medicines suppress the virus. Its November 4, 2025 announcement names entecavir, tenofovir disoproxil fumarate and tenofovir alafenamide.
The goals include preventing cirrhosis, meaning severe liver scarring, and other liver complications. A thymalfasin trial does not supply a reason to replace that care or stop an antiviral. Treatment and monitoring decisions belong with the clinician managing the infection.
Where thymosin alpha-1 stands with regulators
As of October 29, 2026, the day this article was written, Singapore's Zadaxin record lists chronic hepatitis B. Its own update date is October 9, 2026. That is a record update, not a new authorization date.
FDA's orphan-drug record marks thymalfasin's hepatitis B indication as not approved. Orphan designation offers development incentives; it does not authorize marketing. The U.S. regulatory history explains that distinction.
Thymosin alpha-1 prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication. Thymosin alpha-1 has never had an FDA-approved product in the United States, and the compounded formulation offered here is not FDA-approved. A licensed provider may still prescribe — that decision is between you and your doctor.
As of October 29, 2026, the day this article was written, thymosin alpha-1 is absent from the Department of Health and Human Services' list of six peptides. The department, known as HHS, announced the draft in a notice filed October 28; the HHS policy explainer covers its six-peptide list and conditions.
What belongs in the visit
A useful visit covers what the person hopes for, every medicine they take and who manages their liver care, and weighs those against what the research found. These trials did not establish that a compounded preparation matches the study medicine's effects or safety.
At Promise, a licensed U.S. provider reviews every request, and not everyone qualifies. If a prescription is written, the provider sets the plan and follow-up.
